Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 3/20 | 0.37 |
| ▸ | MGLL | Q99685 | 1/20 | 0.37 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.35 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | TNF | P01375 | 1/20 | 0.33 |
| ▸ | UBE2N | P61088 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10612824 | 0.83 | MAPT (0.39) | RIPK1NPSR1 | |
| SCHEMBL13879561 | 0.82 | MGLL (0.41) | MGLLNPSR1 | |
| SCHEMBL13879483 | 0.82 | GAA (0.47) | NPSR1UBE2N | |
| SCHEMBL13879399 | 0.80 | NPSR1 (0.39) | RIPK1MGLLNPSR1TNFUBE2N | |
| SCHEMBL13879499 | 0.80 | MGLL (0.38) | RIPK1MGLLNPSR1UBE2N | |
| SCHEMBL13879566 | 0.79 | NPSR1 (0.33) | RIPK1NPSR1TNFUBE2N | |
| SCHEMBL13879362 | 0.76 | HSD17B10 (0.34) | NPSR1UBE2N | |
| SCHEMBL13879540 | 0.75 | KMT2A (0.55) | TNF | |
| SCHEMBL13879575 | 0.74 | KDM4E (0.42) | MGLLROCK2ALOX5 | |
| SCHEMBL13879564 | 0.73 | NPSR1 (0.47) | MGLLROCK2NPSR1TNF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090099186-A1 | INHIBITORS OF VIRAL REPLICATION | INTERMUNE, INC. | 2009-04-16 | — | — | US | disclosed |
| US-20090099186-A1 | INHIBITORS OF VIRAL REPLICATION | INTERMUNE, INC. | 2009-04-16 | — | — | US | disclosed |
| WO-2007047146-A2 | INHIBITORS OF VIRAL REPLICATION | INTERMUNE, INC. (US) | 2007-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099186-A1 | INHIBITORS OF VIRAL REPLICATION | EIF2AK2, HAVCR2, RTF2 | RIPK1 3413/4885MGLL 2140/4885ROCK2 1477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.